Pfizer’s Celebrex Could Face Generic At-Risk Launches In May
This article was originally published in The Pink Sheet Daily
Pfizer had hoped to gain an extra 18 months of patent protection with a reissue patent granted last year but a district court ruled the method of use patent is invalid.
You may also be interested in...
Pfizer sues five generic firms alleging their celecoxib ANDAs infringe a reissued method-of-use patent, which protects the blockbuster COX-2 inhibitor until December 2015, 18 months longer than had been expected.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.